Prognostic factors and clinical efficacy of second-line treatments of Pneumocystis jirovecii pneumonia for non-HIV patients after first-line treatment failure

Table 2 Risk factors for second-line treatment failure in PCP infected non-HIV immunocompromised patients by univariate analysis and multivariate analysis

Parameters	Univariate analysis
Parameters	Failure, n = 21	Success, n = 28	P value
Demographic information
Male, n (%)	12 (57)	10 (36)	0.139
Age, yr (range)	50 (26–74)	48 (18–71)	0.678
Underlying disease
RID, n (%)	13 (62)	15 (54)	0.560
Tumor, Organ transplant, and other diseases, n (%)	8 (38)	13 (46)	0.560
TS, n (%)	15 (71)	20 (71)	1.000
Lab examination
WBC, × 10.⁹/L [IQR]	8.1 [5.4]	9.2 [6.3]	0.276
LY, × 10.⁹/L [IQR]	0.5 [0.4]	0.8 [0.8]	0.053
LDH, U/L [IQR]	607 [333]	546 [281]	0.092
BDG, pg/ml [IQR]	924 [1109]	1325 [1749]	0.715
Treatment
C, n (%)	6 (29)	7 (25)	0.779
C-Ca, n (%)	6 (29)	12 (43)	0.307
C-P, n (%)	3 (14)	6 (21)	0.525
C-P-Ca, n (%)	6 (29)	3 (11)	0.122
Co-infection
CMV, n (%)	15 (71)	19 (68)	0.788
Bacteremia, n (%)	8 (38)	13 (46)	0.560

PCP Pneumocystis jirovecii pneumonia, HIV human immunodeficiency virus, OR odds ratio, CI confidence interval, RID rheumatic immune disease, TS typical symptoms of simultaneous breathlessness at rest, persistent fever and cough; SD standard deviation, WBC white blood cell, IQR interquartile range, LY lymphocyte, LDH lactate dehydrogenase, BDG (1–3)-beta-D-glucan, IMV Invasive mechanical ventilation, CMV Cytomegalovirus

ISSN: 1471-2334